Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.

Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of Aβ pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD. • CSF NfL is increased and associated with amyloid pathology in preclinical AD. • Plasma NfL is increased in symptomatic AD. • CSF NfL is associated with reduced white matter microstructure in preclinical AD. • Plasma NfL is associated with reduced white matter microstructure in symptomatic AD. • In 5xFAD mice, NfL in CSF is increased at an earlier time point than in serum. [ABSTRACT FROM AUTHOR]